Cantor Fitzgerald Cuts Earnings Estimates for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Gossamer Bio in a report issued on Monday, May 19th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company will post earnings of ($0.71) per share for the year, down from their previous forecast of ($0.70). The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The company had revenue of $9.89 million during the quarter, compared to analysts' expectations of $3.95 million.

A number of other research analysts have also weighed in on the company. The Goldman Sachs Group raised their price objective on Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Friday, May 16th. Wedbush reaffirmed an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, May 16th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, March 18th.

Gossamer Bio Stock Up 3.4%

Shares of NASDAQ:GOSS traded up $0.04 during trading on Wednesday, hitting $1.20. The stock had a trading volume of 1,930,685 shares, compared to its average volume of 1,550,322. The company has a market capitalization of $272.76 million, a PE ratio of -3.75 and a beta of 1.82. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm's fifty day moving average is $1.02 and its 200 day moving average is $1.00. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.55.

Hedge Funds Weigh In On Gossamer Bio

A number of large investors have recently bought and sold shares of GOSS. Graham Capital Management L.P. purchased a new position in shares of Gossamer Bio in the 4th quarter valued at $32,000. Virtu Financial LLC bought a new stake in Gossamer Bio during the first quarter valued at about $38,000. Invesco Ltd. bought a new stake in Gossamer Bio during the first quarter valued at about $48,000. Fullcircle Wealth LLC purchased a new position in Gossamer Bio in the fourth quarter valued at about $43,000. Finally, Velan Capital Investment Management LP bought a new position in Gossamer Bio in the fourth quarter worth about $68,000. Institutional investors own 81.23% of the company's stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.